The short version of incretin mimetic fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
A mesenchymal–epithelial transition (MET) is a reversible biological process that involves the transition from motile, multipolar or spindle-shaped mesenchymal cells to planar arrays of polarized cells called epithelia. MET is the reverse process of epithelial–mesenchymal transition (EMT) and it has been shown to occur in normal development, induced pluripotent stem cell reprogramming, cancer metastasis and wound healing.
=== Laminin N-terminal === Basement membrane assembly is a cooperative process in which laminins polymerise through their N-terminal domain (LN or domain VI) and anchor to the cell surface through their G domains. Netrins may also associate with this network through heterotypic LN domain interactions. This leads to cell signalling through integrins and dystroglycan (and possibly other receptors) recruited to the adherent laminin. This LN domain-dependent self-assembly is considered to be crucial for the integrity of basement membranes, as highlighted by genetic forms of muscular dystrophy containing the deletion of the LN module from the alpha 2 laminin chain. The laminin N-terminal domain is found in all laminin and netrin subunits except laminin alpha 3A, alpha 4 and gamma 2.
== Applying, wearing and using == Injection ports are usually applied by the patient. The device comes with a needle surrounded by a soft cannula. The needle and cannula are manually inserted into the patient's tissue. Immediately after insertion the needle is removed and the cannula remains below the surface of the skin. Ports are usually worn on the abdomen, but can also be worn on other areas such as the buttocks, thigh or arm. Typical injection ports are worn for 3 days and then replaced with another port. Insulin is injected via a syringe into the injection port. Medication immediately flows through the device's cannula into the subcutaneous tissue layer. No medication is stored in the device (other than the small amount of dead-space in the medication channel within the device).
On 12 December 1994, the 2nd Battalion (Airborne), 505th Infantry, with the 2nd Platoon of Company C, 307th Engineer Battalion, deployed as part of Operations Safe Haven and Safe Passage. The battalion deployed from Fort Bragg "to restore order" against what American officials termed "Cuban refugees" who had attacked and injured a number of Air Force personnel and one marine while protesting their detainment at Empire Range along the Panama Canal. The battalion participated in the safeguarding of the Cuban refugees, a camp cordon and reorganization, and the active patrolling in and around the refugee camps in and around the Panamanian jungle along the Panama canal for two months. General Engineering support in the area of camp establishment/improvement operations was provided by the Sappers of the habitually associated Task Force Panther Engineer platoon, 2/C-307th. Task Force Panther was commanded by LTC Lloyd J. Austin III, who was later the first African American General to commander of US Central Command and US Secretary of Defense. This support included the planning of camp power requirements, pouring of 78 concrete pads, three-foot bridges, a set of "mock doors" for airborne pre-jump training, and a system of decks for the muddy camp. During the deployment, the paratroopers experienced a 92 °F (33 °C) Christmas Day. They returned to Fort Bragg on 14 February 1995.
The meridians (经络, jīng-luò) are believed to be channels running from the zàng-fǔ in the interior (里, lǐ) of the body to the limbs and joints ("the surface" [表, biaǒ]), transporting qi and xuĕ. TCM identifies 12 "regular" and 8 "extraordinary" meridians; the Chinese terms being 十二经脉 (shí-èr jīngmài, lit. "the Twelve Vessels") and 奇经八脉 (qí jīng bā mài) respectively. There's also a number of less customary channels branching from the "regular" meridians.
Sources: en.wikipedia.org
He therefore suggests thinking of civilization as a "highly stable state of matter capable of acquiring, making abstract analysis of, and utilizing information to obtain qualitatively new information about its environment and about itself, to improve its capabilities of gathering new information for producing sustaining reactions." Civilization is therefore characterized by the quality of the information acquired by its operating program, and by the energy required to implement these functions. By "information about its environment and about itself", Kardashev specified that it is data about organic or inorganic nature, science, technology, economy, culture, arts, etc. From this definition, he proposed a diagram representing the interactions between a civilization and its environment, and enumerated a number of scientific problems arising from these interactions with the information available in the Universe. From this definition, Kardashev drew three conclusions. The first postulated that because of the vast and unlimited set of activities required by scientific problems, the period during which civilizations must transmit and communicate is necessarily long, even unlimited. On the other hand, since our present development covers only a negligible fraction of this communication phase, Kardashev hypothesized the high improbability that we will meet "brothers in intelligence" who are at the same stage of evolution as we are.
Yeast extract, made from the intracellular contents of yeast and used as food additives or flavours. The general method for making yeast extract for food products such as Vegemite and Marmite on a commercial scale is heat autolysis, i.e. to add salt to a suspension of yeast, making the solution hypertonic, which leads to the cells' shrivelling up. This triggers autolysis, wherein the yeast's digestive enzymes break their own proteins down into simpler compounds, a process of self-destruction. The dying yeast cells are then heated to complete their breakdown, after which the husks (yeast with thick cell walls that would give poor texture) are removed. Yeast autolysates are used in Vegemite and Promite (Australia); Marmite (the United Kingdom); the unrelated Marmite (New Zealand); Vitam-R (Germany); and Cenovis (Switzerland). Nutritional yeast, which is whole dried, deactivated yeast cells, usually S. cerevisiae. Usually in the form of yellow flake or powder, its nutty and umami flavor makes it a vegan substitute for cheese powder. Another popular use is as a topping for popcorn. It can also be used in mashed and fried potatoes, as well as in scrambled eggs. It comes in the form of flakes, or as a yellow powder similar in texture to cornmeal. In Australia, it is sometimes sold as "savoury yeast flakes". Both types of yeast foods above are rich in B-complex vitamins (besides vitamin B12 unless fortified), making them an attractive nutritional supplement to vegans. The same vitamins are also found in some yeast-fermented products mentioned above, such as kvass.
Honokiol is a lignan isolated from the bark, seed cones, and leaves of trees belonging to the genus Magnolia. It has been identified as one of the chemical compounds in some traditional Eastern herbal medicines along with magnolol, 4-O-methylhonokiol, and obovatol. Honokiol, a compound with a spicy odor extracted from various Magnolia species worldwide, including those native to the Southeastern United States and Mexico, can readily cross the blood-brain and cerebrospinal fluid barriers, making it a highly bioavailable and potentially effective therapeutic agent. Honokiol is a small, hydrophobic neolignan biphenol structurally similar to propofol that can be purified efficiently from its isomer magnolol using advanced chromatography techniques such as magnolol acetonide protection followed by flash chromatography or high-capacity high-speed countercurrent chromatography. Extracts from the bark and seed cones of Magnolia trees have been traditionally used in Chinese, Korean, and Japanese medicine as analgesics and treatments for anxiety and mood disorders, notably in formulas like Houpu in Chinese medicine and Kampo in Japan. Honokiol is a pleiotropic natural compound under preliminary research for antitumor, anti-inflammatory, antioxidant, neuroprotective, and antithrombotic properties, showing therapeutic potential across the central nervous system, cardiovascular system, and gastrointestinal system, though it may pose bleeding risks in patients with hemophilia, Von Willebrand disease, or those on anticoagulant therapy.
The lack of organization structure has led to project cancellations, as it can be difficult to convince other employees to work on them. In 2020, Valve acknowledged that this made it difficult to gather momentum and had slowed its output during the 2010s. Its VR projects and Half-Life: Alyx became a turning point, setting short-term studio-wide goals to focus the company. According to Walker, "We sort of had to collectively admit we were wrong on the premise that you will be happiest if you work on something you personally want to work on the most." In January 2023, People Make Games released a report on Valve's corporate structure and culture, based on interviews with several current and former employees. They found that Valve's flat structure and stack-ranking compensation system created a poor release record and a lack of employee diversity. In 2024, Forbes estimated that Newell owned 50.1% of Valve, with the rest owned by employees. As part of Wolfire Games' lawsuit over Steam policies, case documents revealed details related to Valve's employee structure. Valve had 60 employees in 2003 and had approximately 350 employees between 2012 and 2021. Employees are categorized into administration, game development, Steam development and (from 2011) hardware development.
BRI1-associated receptor kinase 1 (BAK1) is an LRR-RLK found in A. thaliana, which has been proposed to function as an adaptor protein that is required for the proper functioning of other RLKs. Yeast two-hybrid assays have shown that AtPEPR1 and its closest analog, AtPEPR2, interact with BAK1.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.